REX Organization

REX Organization is a clinical-stage biotechnology company focused on the development of pathotropic (disease-seeking) targeted gene therapy products for the treatment of refractory cancers. The company's lead candidate, Rexin-G (REX-G7), is a tumor-targeted injectable vector that delivers a dominant-negative cyclin G1 gene to inhibit cell cycle progression in solid tumors. REX Organization utilizes a proprietary platform technology designed to accumulate therapeutic genes specifically within the tumor microenvironment while sparing healthy tissues. Their pipeline includes several targeted genetic medicines aimed at high-unmet-need indications such as pancreatic cancer and metastatic sarcomas. The company operates as a specialized entity often collaborating with academic and clinical centers to advance its precision oncology portfolio.